[HTML][HTML] Antifibrotic agents for liver disease
E Albanis, SL Friedman - American Journal of transplantation, 2006 - Elsevier
Complications from chronic hepatitis C (HCV) and recurrent HCV post-transplant are
responsible for significant morbidity and mortality in the United States and Europe. Current
antiviral therapies are at best, effective in up to 50% of patients in the pre-transplant setting,
and in the post-transplant setting are associated with more limited efficacy and increased
toxicity. With this reduced efficacy of antiviral strategies in the post-transplant setting, new
approaches are urgently needed. Substantial progress has been made in understanding the …
responsible for significant morbidity and mortality in the United States and Europe. Current
antiviral therapies are at best, effective in up to 50% of patients in the pre-transplant setting,
and in the post-transplant setting are associated with more limited efficacy and increased
toxicity. With this reduced efficacy of antiviral strategies in the post-transplant setting, new
approaches are urgently needed. Substantial progress has been made in understanding the …